Lobbying Disclosures in the US: How Big Pharma Fought the TRIPS Waiver & is Pushing for Strong Intellectual Property Protection in the Pandemic Agreement

Michael Weinstein and Peter Maybarduk

Latest Posts

FDA Approves First Generic Of Lenacapavir

November 2, 2026

A Comprehensive Look at Ebola Outbreaks and Responses

October 30, 2026

Respiratory Infections on the Rise as Dumpster Fires Surge in Tanzania

October 27, 2026

Indonesia’s Budi Sadikin, and His “Build, Grow, Scale” Strategy to Reform WHO

October 23, 2026

“Why Must We End Polio Now” Explains Dr Mohamed Janabi, WHO Regional Director of Africa

October 23, 2026

Talanoa: The Pacific Practice That Could Reshape Global Health Dialogue

October 22, 2026

Zimbabwe’s HIV Progress at Risk from U.S. Funding Cuts

October 19, 2026

WHO Director-General Candidates Address Global Health Reform in First Public Dialogue

October 11, 2026

A Review of Former WHO Director-Generals, and Insights into the Next Vote

October 10, 2026

Ukraine’s HIV Response Holding On Amid Conflict with Russia

October 9, 2026

Experts Urge Strategy to Reward Countries That Report Outbreaks Early

October 8, 2026

New Pandemic Readiness Blueprint Targets the Gaps That Left Millions Unprotected from COVID-19

September 21, 2026